Phase II trial of 96-hour paclitaxel in previously treated patients with advanced esophageal cancer

Cancer Investigation

Volumn 21, Issue 4, 2003, Pages 512-516

  Anderson, Sibyl E ^a,b   O'Reilly, Eileen M ^a,b   Kelsen, David P ^a,b   Ilson, David H ^a,b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

96 Hour infusion; Esophageal cancer; Paclitaxel

Indexed keywords

PACLITAXEL;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER RADIOTHERAPY; CANCER RESISTANCE; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DRUG TOLERABILITY; ESOPHAGUS CANCER; FATIGUE; FEMALE; HUMAN; LUNG CANCER; MALE; MUCOSA INFLAMMATION; NAUSEA; NEUROTOXICITY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT; SQUAMOUS CELL; VOMITING;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CARCINOMA, SQUAMOUS CELL; DISEASE PROGRESSION; ESOPHAGEAL NEOPLASMS; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; PACLITAXEL; TREATMENT OUTCOME;

EID: 0141676699     PISSN: 07357907     EISSN: None     Source Type: Journal    
DOI: 10.1081/CNV-120022360     Document Type: Article

References (16)

1. Greenlee, R.T.; Hill-Harmon, M.B.; Murray, T.; et al. CA Cancer J. Clin. 2001, 51, 15-36.
2. Ilson, D.H.; Bains, M.; Ginsberg, R.J.; Kelsen, D.P. Neoadjuvant therapy of esophageal cancer. Surg. Oncol. Clin. N. Am. 1997, 6, 723-740.
3. Rowinsky, E.K.; Donehower, R.C. Drug therapy: paclitaxel (paclitaxel). N. Engl. J. Med. 1995, 332, 1004-1014.
4. Chang, A.Y.; Boros, L.; Garrow, G.; et al. Paclitaxel by 3-hour infusion followed by 96-hour infusion on failure in patients with refractory malignant disease. Semin. Oncol. 1995, 22 (Suppl. 6), 24-127.
5. Schiff, P.B.; Horowitz, S.B. Molecular Actions and Targets for Cancer Chemotherapeutic Agents; Sartorelli, A.C., Laso, J.S., Bertino, J.R., Eds.; Bristol Myers Symposia; Academic Press: New York, 1981; Vol. 2, 483-507.
6. Seidman, A.D.; Hochhauser, D.; Gollub, M.; et al. Ninety-six paclitaxel infusion after progression during short taxane exposure: a phase II pharmacokinetic and pharmacodynamic study in metastatic breast cancer. J. Clin. Oncol. 1996, 14 (6), 1874-1877.
7. Socinski, M.A.; Steagall, A. Phase II trial of 96 hour paclitaxel infusion in patients with non-small cell lung cancer failing previous platinum based or short duration paclitaxel therapy. Proc. Am. Soc. Clin. Oncol. 1997, 1735, (abstr), 535.
8. Miller, A.B.; Hoogstraten, B.; Staquet, M.; et al. Reporting results of cancer treatment. Cancer 1981, 47, 207-214.
9. Gehan, E.A. The determination of the number of patients required in a preliminary and follow-up of a new chemotherapeutic agent. J. Chron. Dis. 1961, 13, 346-353.
10. Wilson, W.L.; Berg, S.L.; Bryant, G.; et al. Paclitaxel in doxorubicin-refractory or mitoxanthrone-refractory breast cancer: a phase I/II trial of 96-hour infusion. J. Clin. Oncol. 1994, 12, 1621-1629.
11. Socinski, M.A.; Steagall, A.; Gillenwater, H. Second-line chemotherapy with 96-hour infusional paclitaxel in refractory non-small cell lung cancer: report of a phase II trial. Cancer Investig. 1999, 173, 181-188.
12. Ajani, J.A.; Ilson, D.H.; Daugherty, K.; et al. Activity of paclitaxel in patients with squamous cell carcinoma and adenocarcinoma of the esophagus. JNCI, 86(14): 1086-1091.
13. Ilson, D.H.; Ajani, J.A.; Bhalla, K.; et al. Phase II trial of paclitaxel, fluorouracil, and cisplatin in patients with advanced carcinoma of the esophagus. J. Clin. Oncol. 1998, 16 (5), 1826-1834.
14. Ilson, D.H.; Forastiere, A.; Arquette, M.; et al. A phase II trial of paclitaxel and cisplatin in patients with advanced carcinoma of the esophagus. Ca J. Sci. Am. 2000, 6 (5), 316-323.
15. Kelsen, D.P.; Ilson, D.H.; Wadleigh, R.; et al. A phase II multi-center trial of paclitaxel as a weekly one-hour infusion in advanced esophageal cancer. PASCO no. 1266, 2000.
16. Kelsen, D.; Ilson, B.; Lipton, B.; et al. Phase I trial of combined modality therapy for localized esophageal cancer: radiation therapy and concurrent cisplatin and escalating doses of 96 hour infusion paclitaxel. PASCO no. 1000, 1998.